▲ +26.51% Upside Potential
This price target is based on 19 analysts offering 12 month price targets for DexCom in the last 3 months. The average price target is $406.22, with a high forecast of $500.00 and a low forecast of $230.00. The average price target represents a 26.51% upside from the last price of $321.09.
The current consensus among 19 polled investment analysts is to buy stock in DexCom. This Buy consensus rating has held steady for over two years.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, a CGM system for diabetes management; DexCom G5 mobile CGM system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop a series of next-generation CGM products; and a collaboration with Companion Medical, Inc. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.